Actor
GBC-HpVac SA
Focused on the development of GBC-R1 as a preventive and therapeutic first-line therapy against asthma, eczema, food allergies and related allergic diseases, as well as inflammatory bowel conditions such as Crohn’s disease and ulcerative colitis.
Specialties
Primary Therapeutic Areas
1.0 Therapeutic & Diagnostic
1.00 Antibodies & Anti-infectious
1.09 Proteins & Peptides
1.10 Small Molecules
1.11 Vaccine
1.2 R&D Services
1.34 Therapeutic
Business model
1. Entreprise
1.1 Start-Up
Organization Type
Private Company
Visit website
Domains
Dermatology, Immunology & Allergy
Main sector
Biotech
Contact
15, Avenue de Sécheron
1202 Geneva / GE